Skip to main content

Animal Health Market Insights- Fall 2024

Animal Health
Consumer
Healthcare
Vet Services

Market Outlook

Key Trends in Companion Animal Health

  • 70% of U.S. households own pets, approximately half of which own more than one pet.
    • Millennials make up the largest percentage of current pet owners (33%), followed by Gen X (25%), and baby boomers (24%)
      • Millennials have shown a preference for marrying later than older generations, and in many cases, choosing instead to adopt pets. Millennials account for 33% of current U.S. pet owners, despite accounting for ~22% of the total U.S. population.
    • There are an estimated 86.3 million dogs and 61 million cats in the U.S., and more than twice that amount across the rest of the world.
  • The humanization of pets, a trend describing the growing share of individuals that think of their pets as a “member of the family,” is driving growth of pet-related products and services.
  • Research indicates that nearly all pet owners (97%) consider their pets to be a part of their family, and more than half of pet owners (51%) consider their pets to be as much a part of their family as a human family member
  • This trend is a key driver of growth as pet owners are showing an ongoing willingness to pay for pet healthcare products and services even in turbulent economies.

Industry Snapshot

$147B
Total U.S. pet industry spend in 2023 across food, treats, veterinary care, and supplies70%
Of U.S. households own pets

97% 
Of pet owners consider pets family

86.3M Dogs & 61M cats
Estimated U.S. pet population, more than double that of any other country

41,000
Additional veterinarians needed by 2030 to meet rising demand for care

15.3% CAGR
Projected growth in the U.S. animal health diagnostics market through 2030

Bar chart showing growth in the global animal health market size over time, with steady increases each year. Below, a comparison table titled "Human Health vs. Animal Health – Considerations" outlines differences between the two across several dimensions. Key differences include: trial process (multiple species vs. direct to species), approval standards (standard of care vs. placebo), generics impact (steep vs. modest decline), buyer access (complex vs. direct), pay model (intermediate payers vs. private pay), development costs (over $1B vs. under $100M), time to market (9+ years vs. 3–7 years), and risk of market adoption (very high vs. lower).